MAP Pharma re-submits Levadex to the FDA for treatment of Migraine

MAP Pharmaceuticals, has announced that it has re-submitted its New Drug Application (NDA) to the FDA for Levadex, orally inhaled migraine drug ,for the potential acute treatment of Migraine in adults. MAP Pharmaceuticals has entered into a collaboration agreement with Allergan to co-promote Levadex to neurologists and pain specialists in the U.S. and Canada. MAP Pharmaceuticals retains all rights to commercialize Levadex outside the U.S., as well as to primary care physicians within the U.S. and Canada.